1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Drugs In Development, 2022, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 48, 20, 1, 4, 56, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 5, 5, 1, 16 and 1 molecules, respectively.
Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Neuroblastoma - Overview
- Neuroblastoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Neuroblastoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Neuroblastoma - Companies Involved in Therapeutics Development
- Neuroblastoma - Drug Profiles
- Neuroblastoma - Dormant Projects
- Neuroblastoma - Discontinued Products
- Neuroblastoma - Product Development Milestones
- Featured News & Press Releases
- Oct 28, 2022: Y-mAbs announces scheduling of FDA advisory committee meeting for Omburtamab
- Oct 03, 2022: Y-mAbs announces pivotal data for Omburtamab
- Sep 26, 2022: Y-mAbs announces regulatory filing for DANYELZA (naxitamab-gqgk) in Brazil
- Aug 30, 2022: Y-mAbs and Takeda announces marketing authorization in Israel for DANYELZA (naxitamab-gqgk) for neuroblastoma
- Jul 26, 2022: The global pharmaceutical industry is accelerating; Aptorum Group has received orphan drug designation from US FDA for its SACT-1
- Jun 28, 2022: SciClone Pharmaceuticals : NMPA approval of IND of DANYELZA (naxitamab) and GM-CSF in combination with Irinotecan and Temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse
- Jun 03, 2022: Y-mAbs announces Naxitamab chemoimmunotherapy investigational trial for high-risk neuroblastoma meets primary endpoint
- May 31, 2022: Y-mAbs announces FDA Acceptance of Biologics License Application for OMBLASTYS (omburtamab) for the treatment of Neuroblastoma for Priority Review
- May 02, 2022: Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to present phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASGCT 25th Annual Meeting
- May 02, 2022: Aptorum Group updates on data from the completed phase 1 clinical trial of SACT-1, targeting neuroblastoma
- Apr 23, 2022: Nektar and collaborators present preclinical data on NKTR-255, a novel IL-15 receptor agonist, in combination with CAR cell therapies at the 2022 Tandem Meetings - Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
- Apr 20, 2022: Nmpa acceptance of IND of Danyelza (naxitamab) and GM-CSF in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse
- Mar 21, 2022: Ascentage Pharma's MDM2-p53 inhibitor alrizomadlin (APG-115) granted Rare Pediatric Disease Designation by the US FDA for the treatment of neuroblastoma
- Feb 11, 2022: Y-mAbs announces completion of Pre-BLA meeting with FDA for Omburtamab
- Jan 20, 2022: Aptorum Group receives FDA Orphan Drug Designation for its SACT-1 repurposed drug for the treatment of neuroblastoma
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Neuroblastoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Neuroblastoma - Dormant Projects, 2022
- Neuroblastoma - Discontinued Products, 2022
- Number of Products under Development for Neuroblastoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ability Pharmaceuticals SL
- Actuate Therapeutics Inc
- ADC Therapeutics SA
- Adicet Bio Inc
- Advanced Accelerator Applications SA
- Advanced Innovative Partners Inc
- Advenchen Laboratories LLC
- Alaunos Therapeutics Inc
- Alissa Pharma
- Aptorum Group Ltd
- Arromax Pharmatech Co Ltd
- Ascentage Pharma Group International
- AstraZeneca Plc
- Athenex Inc
- AUM Biosciences Pte Ltd
- Autolus Therapeutics Plc
- Bayer AG
- Bellicum Pharmaceuticals Inc
- Bio-Cancer Treatment International Ltd
- Biocad
- BioEclipse Therapeutics Inc
- Biogenera SpA
- BioLineRx Ltd
- Biosceptre International Ltd
- Bristol-Myers Squibb Co
- Cebiotex SL
- Cellectar Biosciences Inc
- Chiome Bioscience Inc
- Clarity Pharmaceuticals Ltd
- Collaborations Pharmaceuticals Inc
- CorMedix Inc
- Cothera Bioscience Pty Ltd
- Curis Inc
- Cyclacel Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- DeepCure Inc
- DEKK-TEC Inc
- DOSE Therapeutics Inc
- Edison Oncology Holding Corp
- Eli Lilly and Co
- Epigene Therapeutics Inc
- Epizyme Inc
- Exelixis Inc
- Expression Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- GAiA BioMedicine Inc
- Gate2Brain SL
- Gibson Oncology LLC
- GSK plc
- Helixmith Co Ltd
- Innovent Biologics Inc
- Invenra Inc
- Ipsen SA
- Jubilant DraxImage Inc
- KC Pharma LLC
- Lantheus Holdings Inc
- Lead Discovery Center GmbH
- LegoChem Biosciences Inc
- MacroGenics Inc
- Mana Therapeutics Inc
- MediaPharma SRL
- Merck & Co Inc
- Nanjing CART Medical Technology Co Ltd
- Nanogenics Ltd
- NanoPharmaceuticals LLC
- Nektar Therapeutics
- Novartis AG
- NovoMedix LLC
- Nurix Therapeutics Inc
- Nuvalent Inc
- OBI Pharma Inc
- OGD2 Pharma SAS
- Oncolys BioPharma Inc
- Onconova Therapeutics Inc
- OncoTherapy Science Inc
- Ono Pharmaceutical Co Ltd
- Open Therapeutics LLC
- Orgenesis Inc
- Orphelia Pharma SAS
- Panbela Therapeutics Inc
- Peel Therapeutics Inc
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pfizer Inc
- Progenics Pharmaceuticals Inc
- Provectus Biopharmaceuticals Inc
- PYC Therapeutics Ltd
- Qualigen Therapeutics Inc
- Recombio SL
- Recordati SpA
- Ribomic Inc
- Rophibio Inc
- San Rocco Therapeutics LLC
- Sapience Therapeutics Inc
- SciTech Development LLC
- Secura Bio Inc
- Seneca Therapeutics Inc
- Senhwa Biosciences Inc
- Shionogi & Co Ltd
- SignalRx Pharmaceuticals Inc
- Sinobioway Cell Therapy Co Ltd
- SMTPH Ltd
- Sorrento Therapeutics Inc
- Statera Biopharma Inc
- Stemsynergy Therapeutics Inc
- T-Cure Bioscience Inc
- Tactiva Therapeutics LLC
- TC BioPharm Ltd
- Tmunity Therapeutics Inc
- Toko Pharmaceutical Industries Co Ltd
- Trellis Bioscience Inc
- TroBio Therapeutics Pty Ltd
- UGISense AG
- UTC Therapeutics Inc
- Wigen Biomedicine Technology (Shanghai) Co Ltd
- Xcovery Holding Co LLC
- Y-mAbs Therapeutics Inc
